CT-guided biopsy of pulmonary nodules: is pulmonary hemorrhage a complication or an advantage?

PURPOSE

We aimed to assess the correlation between pulmonary hemorrhage and pneumothorax in computed tomography (CT)-guided transthoracic fine needle aspiration (TTFNA), particularly its possible value as protection against the development of pneumotorax.

MATERIALS AND METHODS

We reviewed the CT images of 538 patients (364 males and 174 females, mean age 70 years, range 36–90 years) who underwent CT-guided TTFNA of pulmonary nodules between January 2008 and September 2013. The following CT findings were assessed: pulmonary hemorrhage (type 1, along the needle track; type 2, perilesional; low-grade, ≤6 mm; high-grade, >6 mm), pneumothorax, distance between the target nodule and the pleural surface, and emphysema.

RESULTS

Pneumothorax occurred in 154 cases (28.6%) and pulmonary hemorrhage occurred in 144 cases (26.8%). The incidence of pneumothorax was lower in patients showing type 1 and high-grade pulmonary hemorrhage pattern. The incidence of pneumothorax in biopsies ≥30 mm from pleural surface was 26% (12/46) in cases showing this pattern, while it was 71.4% (30/42) when this pattern was not seen. Similarly, the incidence of pneumothorax in biopsies <30 mm from the pleural surface was 0% (0/28) in cases showing this hemorrhage pattern, while it was 19% (76/394) when this pattern was not seen.

CONCLUSION

Pulmonary hemorrhage during TTFNA is a frequent event that protects against pneumothorax. A bleeding greater than 6 mm along the needle track is associated with lower incidence of pneumothorax, especially in biopsies deeper than 3 cm.Computed tomography (CT)-guided transthoracic fine needle aspiration (TTFNA) biopsy is currently considered a reliable diagnostic technique to assess malignancy of pulmonary nodules and masses (1–4). CT-guided TTFNA is an invasive technique with low incidence of severe complications and contraindications (1).Pneumothorax is the most common complication occurring in the range of 8%–64% (with a risk of tension pneumothorax in about 7% of cases) (1–7). The risk of pneumothorax increases in the presence of obstructive lung disease and small target lesion. Furthermore, the risk of pneumothorax is directly related to the distance of the lesion from the pleural surface, number of pleural needle passages, fissures crossing, patient’s age, and operator experience (8). Pulmonary hemorrhage is the second most frequent complication of TTFNA. Pulmonary hemorrhage is rarely the cause of death and it may be associated with hemoptysis in 4%–5% of patients, even as a postprocedure complication (9). According to recent studies, the incidence of pulmonary hemorrhage ranges 15%–26%, depending on the distance of the pulmonary nodule from the pleural surface (10). Higher incidence of pulmonary hemorrhage is related to central or cavitated lesion, presence of bronchiectasis, and larger needles (11–13).The aim of this study was to assess the correlation between pulmonary hemorrhage and pneumothorax in CT-guided TTFNA.     

Vacuum-assisted stereotactic biopsy for isolated BI-RADS 4 microcalcifications: evaluation with histopathology and midterm follow-up results

PURPOSE

The aim of this study was to evaluate the 10-gauge vacuum-assisted stereotactic biopsy (VASB) of isolated Breast Imaging Reporting and Data System (BI-RADS) 4 microcalcifications, using histology and follow-up results.

METHODS

From January 2011 to June 2013, VASB was performed on 132 lesions, and 66 microcalcification-only lesions of BI-RADS 4 were included into our study. VASB was performed using lateral decubitis stereotaxy for all patients. Pathologic results of VASB and further surgical biopsies were reviewed retrospectively. Patients who were diagnosed to have benign lesions by VASB were referred for follow-up. VASB and surgical histopathology results were compared to determine the underestimation ratios.

RESULTS

Fifteen out of 66 lesions from 63 patients (median age, 47 years; range, 34–88 years) were identified as malignant by VASB. Pathological results after surgery revealed three cases of invasive ductal carcinoma among the 12 VASB-diagnosed ductal carcinoma in situ (DCIS) lesions, for a DCIS underestimation rate of 25%. The atypical ductal hyperplasia underestimation rate was 0% for the three lesions. The follow-up period was at least 10 months, with an average of 22.7 months for all patients and 21.2 months for patients with VASB-diagnosed benign lesions. None of the patients had malignancy during the follow-ups. The false-negative rate was 0% in the follow-up of 48 patients.

CONCLUSION

VASB should be the standard method of choice for BI-RADS 4 microcalcifications. This method obviates the need for a surgical procedure in 73% of BI-RADS 4 microcalcification-only patients.Recently, growing concern regarding breast cancer has resulted in increasingly frequent recommendations for screening mammography and more intensive requirements for biopsies of subclinical (impalpable) lesions. Microcalcifications may be the only finding of early stage malignancies, including atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS). Isolated microcalcifications comprise 55% of the suspicious lesions detected by mammography (1, 2).Until recently, the most common approach for this type of pathology has been surgical excision of the lesion after wire localization by mammographic guidance. However, studies have shown that surgical excisions result in benign histology in 76%–81% of the cases (3, 4). Understandably, surgical excisions generate anxiety in most patients. Additionally, the cost and morbidity associated with the surgical procedures have prompted many physicians to explore less invasive, alternative procedures (5–7).For the past two decades, vacuum-assisted stereotactic biopsy (VASB) has been increasingly used for histologic diagnosis of suspicious microcalcifications. The 11-gauge VASB allows radiologists to obtain a sufficiently large specimen with better calcification retrieval (8), a lower re-biopsy rate, and fewer histologic underestimates (9–11), compared with other core-needle biopsy techniques. The false-negative rate of VASB procedure can be as low as 0.6% when performed by experienced radiologists (12). This technique also has some cost advantages compared to needle-localized surgical biopsy (NLSB)(13).Although numerous studies of VASB under real-time ultrasonography (US) or mammography guidance exist, none have included a sufficient subgroup analysis (2, 14). Core needle biopsy is the cheapest and easiest technique for lesions that can be visualized by US; however, isolated, suspicious microcalcifications can only be sampled by means of stereotaxy. To our knowledge, there is no study that has specifically evaluated isolated Breast Imaging Reporting and Data System (BI-RADS) 4 microcalcifications, even though these constitute the majority of subclinical lesions detected by screening mammography. BI-RADS 3 microcalcifications can be followed confidently, whereas BI-RADS 5 microcalcifications should be subjected to surgical excision in all cases.BI-RADS 4 microcalcifications are the most critical issue facing radiologists reporting screening mammography. Through the routine use of VASB for BI-RADS 4 microcalcifications, surgical excision can be avoided in most patients (3, 4). It is important to consider the underestimation and false-negative rates, specifically for isolated BI-RADS 4 microcalcifications, before considering more invasive methods (surgical biopsies) as a further step after VASB. The aim of this study was to evaluate the utility of VASB for isolated BI-RADS 4 microcalcifications by studying their midterm follow-up results.     

MRI features of breast lymphoma: preliminary experience in seven cases

PURPOSE

We aimed to evaluate the imaging features of breast lymphoma using magnetic resonance imaging (MRI).

METHODS

This retrospective study consisted of seven patients with pathologically confirmed breast lymphoma. The breast lymphomas were primary in six patients and secondary in one patient. All patients underwent preoperative dynamic contrast-enhanced MRI and one underwent additional diffusion-weighted imaging (DWI) with a b value of 600 s/mm². Morphologic characteristics, enhancement features, and apparent diffusion coefficient (ADC) values were reviewed.

RESULTS

On MRI, three patients presented with a single mass, one with two masses, two with multiple masses, and one with a single mass and a contralateral focal enhancement. The MRI features of the eight biopsied masses in seven patients were analyzed. On MRI, the margins were irregular in six masses (75%) and spiculated in two (25%). Seven masses (87.5%) displayed homogeneous internal enhancement, while one (12.5%) showed rim enhancement. Seven masses (87.5%) showed a washout pattern and one (12.5%) showed a plateau pattern. The penetrating vessel sign was found in two masses (25%). One patient with two masses underwent DWI. Both masses showed hyperintense signal on DWI with ADC values of 0.867×10⁻³ mm²/s and 0.732×10⁻³ mm²/s, respectively.

CONCLUSION

Breast lymphoma commonly presents as a homogeneously enhancing mass with irregular margins and displays a washout curve pattern on dynamic MRI. A low ADC value may also indicate a possible diagnosis of breast lymphoma.Breast lymphoma, which constitutes only 0.04%–0.5% of all breast malignancies (1), can be divided into primary or secondary breast lymphoma (2). The majority of breast lymphomas are diffuse large B-cell lymphoma (3). The spontaneous regression of a breast lymphoma is rare and the five-year overall survival rate is 53% (1, 4). Early-stage identification and the use of radiotherapy are favorable prognostic factors, while mastectomy is associated with a poorer survival (1, 5). Therefore, a preoperative diagnosis of breast lymphoma would mean an earlier diagnosis and likely avoid unnecessary aggressive procedures.Previous studies demonstrated mammographic and ultrasonographic findings of breast lymphoma (6–8). Most lesions were high-density masses without spiculated margins and calcifications on mammography and noncircumscribed hypoechoic masses on ultrasonography (6–8). However, none were pathognomonic.Data on the magnetic resonance imaging (MRI) of breast lymphoma are limited to some single case reports (4, 7, 9–19) and small sample size case series (8, 20–23). The morphology and time-signal intensity curve (TIC) of breast lymphoma on MRI are variable. Diffusion-weighted imaging (DWI) is a functional imaging technique that is useful for distinguishing lymphoma from other malignant tumors in other systems (24, 25). However, to the best of our knowledge, the value of DWI in differentiating breast lymphoma from other malignant breast lesions has not been discussed. Therefore, the purpose of this study is to assess the MRI and DWI features of breast lymphoma.     

Angiographic analysis of the lateral intercostal artery perforator of the posterior intercostal artery: anatomic variation and clinical significance

PURPOSE

Knowledge of the anatomic variations of the posterior intercostal artery (PICA) and its major branches is important during transthoracic procedures and surgery. We aimed to identify the anatomic features and variations of the lateral intercostal artery perforator (LICAP) of the PICA with selective PICA arteriography.

METHODS

We retrospectively evaluated 353 PICAs in 75 patients with selective PICA arteriography for the following characteristics: incidence, length (as number of traversed intercostal spaces), distribution at the hemithorax (medial half vs. lateral half), and size as compared to the collateral intercostal artery of the PICA.

RESULTS

The incidence of LICAPs was 35.9% (127/353). LICAPs were most commonly observed in the right 8th–11th intercostal spaces (33%, 42/127) and in the medial half of the hemithorax (85%, 108/127). Most LICAPs were as long as two (35.4%, 45/127) or three intercostal spaces (60.6%, 77/127). Compared to the collateral intercostal artery, 42.5% of LICAPs were larger (54/127), with most of these observed in the right 4th–7th intercostal spaces (48.8%, 22/54).

CONCLUSION

We propose the clinical significance of the LICAP as a potential risk factor for iatrogenic injury during posterior transthoracic intervention and thoracic surgery. For example, skin incisions must be as superficial as possible and directed vertically at the right 4th–7th intercostal spaces and the medial half of the thorax. Awareness of the anatomical variations of the LICAPs of the PICA will allow surgeons and interventional radiologists to avoid iatrogenic arterial injuries during posterior transthoracic procedures and surgery.The incidence of injury to the intercostal artery has increased with growing use of percutaneous transthoracic interventions (e.g., transthoracic biopsy, thoracentesis, thoracostomy, and therapeutic needle puncture procedure) through intercostal spaces. This inadvertent injury to the intercostal artery, especially the posterior intercostal artery (PICA), can result in high morbidity and mortality due to acute severe hemothorax (1–3). Since procedures through the posterior intercostal space have become more common, precise knowledge of anatomy is necessary to avoid injuring the PICA. Several studies have been conducted to evaluate PICA anatomy using computed tomography angiography (4, 5) or cross-sectional anatomy (6, 7).The lateral intercostal artery perforator (LICAP), one of the major branches of the PICA, is well known as a major perforator of the latissimus dorsi muscle flap in the field of plastic surgery (8). It is frequently observed as a vertical branch of the PICA during bronchial artery embolization or transcatheter arterial chemoembolization and has been found frequently to be larger than the collateral intercostal artery, crossing several intercostal spaces. However, to the best of our knowledge, no previous study specifically addressed the anatomic features and clinical significance of the LICAP in the fields of angiography and transthoracic intervention.The aim of this study was to identify the anatomic features and the clinical significance of the LICAP in the fields of angiography and transthoracic surgery through the analysis of various angiographic findings and a comparative analysis of cross-sectional anatomy.     

Adverse effects of irreversible electroporation of malignant liver tumors under CT fluoroscopic guidance: a single-center experience

PURPOSE

We aimed to describe the frequency of adverse events after computed tomography (CT) fluoroscopy-guided irreversible electroporation (IRE) of malignant hepatic tumors and their risk factors.

METHODS

We retrospectively analyzed 85 IRE ablation procedures of 114 malignant liver tumors (52 primary and 62 secondary) not suitable for resection or thermal ablation in 56 patients (42 men and 14 women; median age, 61 years) with regard to mortality and treatment-related complications. Complications were evaluated according to the standardized grading system of the Society of Interventional Radiology. Factors influencing the occurrence of major and minor complications were investigated.

RESULTS

No IRE-related death occurred. Major complications occurred in 7.1% of IRE procedures (6/85), while minor complications occurred in 18.8% (16/85). The most frequent major complication was postablative abscess (4.7%, 4/85) which affected patients with bilioenteric anastomosis significantly more often than patients without this condition (43% vs. 1.3%, P = 0.010). Bilioenteric anastomosis was additionally identified as a risk factor for major complications in general (P = 0.002). Minor complications mainly consisted of hemorrhage and portal vein branch thrombosis.

CONCLUSION

The current study suggests that CT fluoroscopy-guided IRE ablation of malignant liver tumors may be a relatively low-risk procedure. However, patients with bilioenteric anastomosis seem to have an increased risk of postablative abscess formation.About 70% of hepatic metastases are nonresectable because of their anatomic location, the presence of comorbidities, or limited hepatic functional reserve (1). In these patients and in case of nonresectable primary liver tumors, percutaneous thermal ablation procedures, such as radiofrequency (RF) and microwave ablation, have become effective tools for treating hepatic malignancies (2–4). However, the effectiveness of RF and microwave treatment may be limited, either because of thermal damage to temperature-sensitive structures located in close proximity to the target tissue (5) or because of incomplete ablation of tumors adjacent to major hepatic vessels due to a phenomenon commonly termed “heat-sink effect” (6–10) which describes the loss of the applied thermal energy through the blood flow in those major vessels, whereby the effective energy application remains inadequate to ablate the target lesion.Irreversible electroporation (IRE) is a theoretically nonthermal ablation technique that delivers a series of high-voltage millisecond electrical pulses to the surrounding tissue, thus leading to irreversible disruption of the integrity of cell membranes and subsequent cell death by apoptosis (11–14). IRE may overcome the problems raised with thermal ablation: previous animal studies reported that bile ducts, blood vessels, nerves, and connective tissues are affected by IRE; however, regeneration is possible to some extent due to preservation of the tissue architecture (12, 13, 15–19). Moreover the feasibility of inducing cell death up to a vessel wall without any perivascular sparing was shown with IRE (12, 13, 18). The safety of IRE in the treatment of humans has been described (20). First reports have described potential complications after IRE, such as hemorrhage requiring blood transfusion (1.2%, two of 167 ablation procedures), portal vein thrombosis (3.2%, one of 31 ablation procedures), injury to bile ducts (1.8%, three of 167 ablation procedures), and infection (3.6%, six of 167 ablation procedures) (21, 22). However, few data are available for evaluating the potential risk factors associated with the occurrence of post-IRE complications.The purpose of this study was to review the frequency of mortality and morbidity after computed tomography (CT) fluoroscopy-guided liver IRE conducted at a single center and assess the factors influencing the occurrence of major complications.     

Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases

PURPOSE

We aimed to evaluate the effectiveness and safety of radioembolization with yttrium-90 (⁹⁰Y) microspheres in cases with unresectable neuroendocrine tumor liver metastases (NETLMs).

METHODS

Thirty patients (mean age, 55 years) underwent resin-based ⁹⁰Y radioembolization for unresectable NETLM at a single institution between April 2008 and June 2013. Post-treatment tumor response was assessed by cross-sectional imaging using the Response Evaluation Criteria in Solid Tumors (RECIST). Prognostic variables that affected survival were determined.

RESULTS

The mean follow-up was 23.0±19.4 months and the median overall survival was 39 months (95% CI, 12.6–65.4 months), with one- and two-year survival rates of 71% and 45%, respectively. Imaging follow-up using RECIST at three-month intervals demonstrated partial response in 43%, complete remission in 3%, stable disease in 37%, and progressive disease in 17% of patients. Extent of tumor involvement was found to have a statistically significant influence on overall survival (P = 0.03). The existence of extrahepatic disease at the time of radioembolization, radiographic response, age, and primary neuroendocrine tumor site were not significant prognostic factors.

CONCLUSION

The current study demonstrates the effectiveness and safety of radioembolization for the treatment of unresectable NETLMs. We identified that the extent of tumor involvement has a significant effect on overall survival. The use of imaging methods reflecting metabolic activity or cellularity such as scintigraphy or diffusion-weighted MRI would be more appropriate, for the response evaluation of liver metastases after radioembolization.Neuroendocrine tumors (NETs) are a heterogenous group of slow-growing and hormon-releasing malignant tumors. Even though primary NETs originate from a number of locations, 40%–70% of all carcinoids arise in the small intestine and appendix (1, 2). The most common site for metastasis is the liver. Neuroendocrine tumor liver metastasis (NETLM) results in hormone-secretion-related symptoms leading to carcinoid syndrome, pressure on structures, or liver replacement (1–4). Patients with liver metastasis have a five-year survival rate of less than 20% (5). Over the years, improvements in local treatments yielded better control of the symptoms and survival rates, yet only 10% of the patients have limited illness and are eligible for surgery (6). Patient symptomatology and survival can be improved by transarterial treatments like embolization and chemoembolization (6). Limitations of these techniques include the short duration of the effects and the controversial approaches regarding the optimal timing and sequence of the procedures due to the variability of tumor progression (7, 8). Long-term survival benefit was not achieved with systemic chemotherapy (9–11) and treatment with somatostatin analogues is mostly associated with symptomatic relief; there is no clear knowledge of their effect on survival of patients who have carcinoid tumor and metastasis (12).Selective internal radiation therapy (SIRT) has been used to treat unresectable primary and secondary liver cancers for over a decade. Yttrium-90 (⁹⁰Y) is a pure high-energy β emitter with a mean tissue penetration of 2.5 mm. The radioactive microspheres prefer tumoral vascular distribution, so that normal liver tissue is relatively spared and high doses are directed to the tumoral tissue (13). Also, radioembolization-related acute and subacute toxicities are seemingly more tolerable than the ones related to other hepatic embolization procedures (14–16). In this study, we aimed to evaluate the effectiveness and safety of ⁹⁰Y microspheres in cases with unresectable NETLMs.     

MRI-guided core needle biopsy of the prostate: acceptance and side effects

PURPOSE

We aimed to study side effects, complications, and patient acceptance of magnetic resonance imaging-guided real-time biopsy (MRI-GB) of the prostate.

METHODS

Fifty-four men (49–78 years) with elevated prostate-specific antigen after at least one negative systematic transrectal ultrasound-guided biopsy (TRUS-GB) were included in a prospective clinical study. Suspicious areas on images were selectively sampled by obtaining a median of four specimens (range, 1–9 specimens) using MRI-GB. In TRUS-GB, a median of 10 specimens (range, 6–14 specimens) were obtained. Telephone interviews were conducted one week after outpatient MRI-GB, asking patients about pain and side effects (hematuria, hemospermia, rectal bleeding, fever, and chills) of the two biopsy procedures and which of the two procedures they preferred. Multinomial regression analysis and Fisher’s exact test was used to test for differences.

RESULTS

MRI-GB was preferred by 65% (35/54), and 82% (44/54) would undergo MRI-GB again. Pain intensity (P = 0.005) and bleeding duration (P = 0.004) were significantly lower for MRI-GB compared with TRUS-GB. Hematuria was less common after MRI-GB compared with TRUS-GB (P = 0.006). A high correlation was given between bleeding intensity and bleeding duration for TRUS-GB (r=0.77) and pain intensity and pain duration for MRI-GB (r=0.65). Although hemospermia, rectal hemorrhage, fever, and chills were less common in MRI, they showed no statistically significant difference.

CONCLUSION

MRI-GB of the prostate seems to have fewer side effects and less pain intensity than TRUS-GB and was preferred by the majority of patients.Several new recommendations about routine prostate-specific antigen (PSA) screening were recently published (1). Nevertheless, guidelines still recommend that patients with PSA levels suspicious for prostate cancer should undergo transrectal ultrasound-guided biopsy (TRUS-GB). The likelihood of detecting cancer by the first TRUS-GB is below 60% and only 16%–29% for repeat biopsy (2, 3). However, a negative systematic TRUS-GB does not definitely rule out prostate cancer in patients with a persistent clinical suspicion (4, 5). In this situation, multiparametric magnetic resonance imaging (MRI) including diffusion-weighted imaging, dynamic contrast-enhanced MRI, and magnetic resonance spectroscopy is being increasingly used to detect prostate cancer and confirm the diagnosis by MRI-guided biopsy (MRI-GB) (6).While several studies are available on the side effects, complications, and pain experienced by patients who undergo TRUS-GB, no study has been published on the acceptance and side effects of MRI-GB of the prostate (7–9). We therefore conducted a survey among patients who underwent MRI-GB of suspicious areas detected by MRI after a history of at least one negative TRUS-GB. The aim of this survey was to evaluate the acceptance of MRI-GB of the prostate in terms of side effects and complications in comparison with TRUS-GB.     

Endovascular management of iatrogenic renal arterial lesions and clinical outcomes

PURPOSE

We aimed to evaluate iatrogenic renal arterial lesions, including pseudoaneurysm, arteriovenous fistula, and arteriocaliceal fistula, their management by endovascular embolization, and the clinical results.

METHODS

Fifty-five patients (forty males, fifteen females) with a median age of 40 years (range, 8–85 years), who underwent endovascular embolization of iatrogenic renal arterial lesions between March 2003 and December 2013 were included in this retrospective study. Types of iatrogenic lesions and details of embolization procedures were reported. Estimated glomerular filtration rate (eGFR), renal function tests, hemoglobin, and hematocrit levels before and after embolization were recorded and compared.

RESULTS

Median follow-up was 24 months. We identified 53 pseudoaneurysms, 30 arteriovenous fistulas, and 11 arteriocaliceal fistulas in 55 patients, after percutaneous nephrolithotomy (n=26), renal biopsy (n=21), nephrostomy (n=3), renal surgery (n=3), and extracorporeal shock wave lithotripsy (n=2). Median number of pseudoaneurysms was 1 (range, 1–4) with a median size of 7 mm (range, 1.5–35 mm). Fifty-one patients underwent coil embolization. Median number of coils was 5 (range, 2–21) and median renal parenchymal loss was 5% (range, 1%–50%). There were no significant differences between pre- and postoperative eGFR and serum parameters.

CONCLUSION

Iatrogenic renal arterial lesion can be a life threatening condition. Superselective coil embolization is a safe, minimally invasive treatment option with minimal renal parenchymal loss and without significant change in renal function.Iatrogenic renal arterial lesions including pseudoaneurysm (PA), arteriovenous fistula (AVF), and arteriocaliceal fistula (ACF) are rare, but life-threatening conditions (1). The chief symptom usually includes macroscopic hematuria (2, 3). Catheter angiography is the gold standard for both diagnosis and treatment (1).Previous studies have evaluated the iatrogenic renal arterial lesions following partial nephrectomy (1, 3–7), but there were only a few studies on iatrogenic renal arterial lesions following any iatrogenic renal interventions (2). In the present study, to the best of our knowledge, we report the largest series of iatrogenic renal arterial lesions following various renal interventions such as biopsy, percutaneous nephrolithotomy (PCNL), percutaneous nephrostomy, and partial nephrectomy. We focused on clinical presentations, imaging findings, management, and outcomes.     

Single-stage endovascular treatment in patients with severe extracranial large vessel stenosis and concomitant ipsilateral unruptured intracranial aneurysm

PURPOSE

We aimed to evaluate the safety and effectiveness of single-stage endovascular treatment in patients with severe extracranial large vessel stenosis and concomitant ipsilateral unruptured intracranial aneurysm.

METHODS

Hospital database was screened for patients who underwent single-stage endovascular treatment between February 2008 and June 2013 and seven patients were identified. The procedures included unilateral carotid artery stenting (CAS) (n=4), bilateral CAS (n=2), and proximal left subclavian artery stenting (n=1) along with ipsilateral intracranial aneurysm treatment (n=7). The mean internal carotid artery stenosis was 81.6% (range, 70%–95%), and the subclavian artery stenosis was 90%. All aneurysms were unruptured. The mean aneurysm diameter was 7.7 mm (range, 5–13 mm). The aneurysms were ipsilateral to the internal carotid artery stenosis (internal carotid artery aneurysm) in five patients, and in the anterior communicating artery in one patient. The patient with subclavian artery stenosis had a fenestration aneurysm in the proximal basilar artery. Stenting of the extracranial large vessel stenosis was performed before aneurysm treatment in all patients. In two patients who underwent bilateral CAS, the contralateral carotid artery stenosis, which had no aneurysm distally, was treated initially.

RESULTS

There were no procedure-related complications or technical failure. The mean clinical follow-up period was 18 months (range, 9–34 months). One patient who underwent unilateral CAS experienced contralateral transient ischemic attack during the clinical follow-up. There was no restenosis on six-month follow-up angiograms, and all aneurysms were adequately occluded.

CONCLUSION

A single-stage procedure appears to be feasible for treatment of patients with severe extracranial large vessel stenosis and concomitant ipsilateral intracranial aneurysm.The concomitance of severe extracranial large vessel stenosis and unruptured ipsilateral distal intracranial aneurysm is often detected incidentally and their management is not clear (1). Although there are many studies in the literature that report different treatment approaches, there is no definite consensus on the management of the concomitant lesions (2–14). Various treatment options have been suggested, such as initial treatment of the aneurysm before revascularization of the stenosis, treating both lesions in the same surgical session and correcting the stenosis without treating the aneurysm (1, 5, 6, 9–11, 14–16). Few studies have reported single-stage endovascular treatment of both lesions as an effective method (17–19). On the other hand, the treatment of each lesion by this technique may lead to procedure-related undesired events such as cerebral ischemia/stroke or aneurysm rupture.In this study, we aimed to present the radiologic and clinical results of seven consecutive patients who underwent single-stage endovascular treatment of severe extracranial large vessel stenosis and concomitant unruptured ipsilateral intracranial aneurysm and discuss the safety and feasibility of this approach. In addition, distinct from the limited number of similar studies in the literature, we present our experience with bilateral carotid artery stenting (CAS) and proximal subclavian artery stenting during single-stage endovascular treatment.     

Predictive factors for invasive cancer in surgical specimens following an initial diagnosis of ductal carcinoma in situ after stereotactic vacuum-assisted breast biopsy in microcalcification-only lesions

PURPOSE

The aim of this study was to determine the incidence of invasive breast carcinoma in patients with preoperative diagnosis of ductal carcinoma in situ (DCIS) by stereotactic vacuum-assisted biopsy (SVAB) performed for microcalcification-only lesions, and to identify the predictive factors of invasion.

METHODS

From 2000 to 2010, the records of 353 DCIS patients presenting with microcalcification-only lesions who underwent SVAB were retrospectively reviewed. The mammographic size of microcalcification cluster, presence of microinvasion within the cores, the total number of calcium specks, and the number of calcium specks within the retrieved core biopsy specimen were recorded. Patients were grouped as those with or without invasion in the final pathologic report, and variables were compared between the two groups.

RESULTS

The median age was 58 years (range, 34–88 years). At histopathologic examination of the surgical specimen, 63 of 353 patients (17.8%) were found to have an invasive component, although SVAB cores had only shown DCIS preoperatively. The rate of underestimation was significantly higher in patients with microcalcification covering an area of 40 mm or more, in the presence of microinvasion at biopsy, and in cases where less than 40% of the calcium specks were removed from the lesion.

CONCLUSION

Invasion might be underestimated in DCIS cases diagnosed with SVAB performed for microcalcification-only lesions, especially when the mammographic size of calcification is equal to or more than 40 mm or if microinvasion is found within the biopsy specimen and less than 40% of the calcifications are removed. At least 40% of microcalcification specks should be removed from the lesion to decrease the rate of underestimation with SVAB.Because of the widespread use of breast screening mammography, the number of women diagnosed with ductal carcinoma in situ (DCIS) has increased dramatically in recent years. DCIS is a noninvasive form of breast cancer, accounting for up to 30% of breast cancers in screening populations and approximately 5% of breast carcinomas in symptomatic patients (1–3). DCIS has a variety of mammographic presentations, but the most common mammographic feature is microcalcification (4). Indeed 80%–90% of DCIS lesions present with microcalcifications only, without any accompanying mass lesions (4). Other findings such as masses, nodular abnormalities, dilated retroareolar ducts, architectural distortions, and developing densities have also been reported (5).Ultrasound-guided biopsy is often the method of choice for sonographically visible breast lesions as it provides easy access for biopsy. However, in cases when the abnormality seen on mammography is not visible on ultrasonography, stereotactic biopsy is the recommended sampling method. For microcalcification-only lesions with no accompanying mass, ultrasonography often fails to identify the site of the lesion; hence, stereotactic biopsy is used more frequently.In most breast units, stereotactic 14-gauge automated core biopsy has been replaced by stereotactic vacuum-assisted biopsy (SVAB) using 8- to 11-gauge needles (6). Large core SVAB allows larger samples to be obtained in a shorter period of time compared with samples obtained using automated core biopsy devices (7). Moreover, this technique has the advantage of a single insertion in the area of interest compared with automated core biopsy devices, which require repeated insertions. Several published articles have shown that SVAB decreased the rate of cancer underestimation and the rate of failure to retrieve breast microcalcifications (8).The management of noninvasive and invasive breast cancers is different and therefore, an accurate preoperative diagnosis is crucial for adequate surgical planning. Underestimation of DCIS lesions occurs when an invasive component is found after surgery, which had been missed at the initial preoperative sampling. The underestimation rate of stereotactic 14-gauge automated core biopsy in DCIS was reported as 16%–35% (9–11), while that of SVAB was 5%–29% (6, 9, 11–13).The purpose of this study was to determine the rate, causes, and predictive factors of underestimation of invasive carcinoma in patients diagnosed with DCIS following SVAB of microcalcification-only lesions.     

Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session

PURPOSE

A magnetic resonance imaging-ultrasonography (MRI-US) fusion-guided prostate biopsy increases detection rates compared to an extended sextant biopsy. The imaging characteristics and pathology outcomes of subsequent biopsies in patients with initially negative MRI-US fusion biopsies are described in this study.

MATERIALS AND METHODS

We reviewed 855 biopsy sessions of 751 patients (June 2007 to March 2013). The fusion biopsy consisted of two cores per lesion identified on multiparametric MRI (mpMRI) and a 12-core extended sextant transrectal US (TRUS) biopsy. Inclusion criteria were at least two fusion biopsy sessions, with a negative first biopsy and mpMRI before each.

RESULTS

The detection rate on the initial fusion biopsy was 55.3%; 336 patients had negative findings. Forty-one patients had follow-up fusion biopsies, but only 34 of these were preceded by a repeat mpMRI. The median interval between biopsies was 15 months. Fourteen patients (41%) were positive for cancer on the repeat MRI-US fusion biopsy. Age, prostate-specific antigen (PSA), prostate volume, PSA density, digital rectal exam findings, lesion diameter, and changes on imaging were comparable between patients with negative and positive rebiopsies. Of the patients with positive rebiopsies, 79% had a positive TRUS biopsy before referral (P = 0.004). Ten patients had Gleason 3+3 disease, three had 3+4 disease, and one had 4+4 disease.

CONCLUSION

In patients with a negative MRI-US fusion prostate biopsy and indications for repeat biopsy, the detection rate of the follow-up sessions was lower than the initial detection rate. Of the prostate cancers subsequently found, 93% were low grade (≤3+4). In this low risk group of patients, increasing the follow-up time interval should be considered in the appropriate clinical setting.Prostate cancer is the most common cancer in males, with an estimated 238 590 new diagnoses annually in the USA, and it is the second leading cause of cancer-related mortality in males (1). One in six males will develop prostate cancer in his lifetime (1). The current standard of care for diagnosing and grading prostate cancer is a 12-core extended sextant biopsy obtained with transrectal ultrasonography (TRUS) guidance (2, 3). As magnetic resonance imaging (MRI) has superior contrast resolution than ultrasonography (US), it is possible for multiparametric MRI (mpMRI) to detect prostate cancer with high reliability (4). Since clinically insignificant cancer is often invisible to magnetic resonance (MR), prostate MRI preferentially detects more aggressive cancers (5–9). MRI can be used to guide the prostate biopsy, either using a direct “in-gantry” approach or by using MRI-US fusion, which was developed as an office-based alternative (10). MRI-US targeted biopsies have about twice the per-core detection rate of sextant biopsies (11), and have been shown to be particularly useful for prostates measuring greater than 40 mL, which typically have lower rates of cancer detection than smaller prostate glands (12).Since TRUS-guided biopsies have a relatively low sensitivity, many patients with a rising prostate-specific antigen (PSA), but an initial negative biopsy, undergo additional biopsies with progressively lower yields. In a study of sequential systematic biopsies in 1051 males, the detection rate of successive biopsies was 22%, 10%, 5%, and 4%, respectively (13). The third and fourth TRUS-guided biopsy sessions detected lower grade cancers and were found to have higher morbidity than the first two biopsies. Recently, MRI-US fusion biopsy has been reported to increase cancer detection rates in the setting of a prior negative TRUS biopsy (14, 15).While MRI-US fusion biopsy is promising in the setting of previous negative random sampling, the response to a negative MRI-US fusion biopsy is less clear. Since a MRI-US fusion biopsy increases prostate cancer detection, this population should have a lower disease burden than patients with an initial negative TRUS-guided biopsy alone. Now that MRI-US fusion biopsies have been available for several years, such data are beginning to accumulate. Here, we investigate the detection rates of subsequent biopsies in patients with an initial negative MRI-US fusion prostate biopsy.     

Clinical applications of the C-arm cone-beam CT-based 3D needle guidance system in performing percutaneous transthoracic needle biopsy of pulmonary lesions

PURPOSE

This study explored the value of flat detector C-arm CT-guidance system in performing percutaneous transthoracic needle biopsy (PTNB) for lung lesions in clinical practice.

METHODS

A total of 110 patients with solid lung lesions were enrolled to undergo PTNB procedures. The mean diameter of lesions was 4.63 cm (range, 0.6–15cm). The needle path was carefully planned and calculated on the C-arm CT system, which acquired three-dimensional CT-like cross-sectional images. The PTNB procedures were performed under needle guidance with fluoroscopic feedbacks.

RESULTS

Histopathologic tissue was successfully obtained from 108 patients with a puncture success rate of 98.2% (108/110). The diagnostic accuracy rate was found to be 96.3% (104/108). There was only one case of pneumothorax (0.9%) requiring therapy. The rates of mild pneumothorax and hemoptysis were low (12.0% and 6.5%, respectively). In addition, procedural time could be limited with this technique, which helped to reduce X-ray exposure.

CONCLUSION

Our study shows that C-arm CT-based needle guidance enables reliable and efficient needle positioning and progression by providing real-time intraoperative guidance.Lung cancer is the commonest cause of a pulmonary mass, which can be identified through chest X-ray or computed tomography (CT) examinations (1, 2). Accurate identification of histopathological cell type is crucial to determine the right treatment method and reduce the morbidity and mortality rates. Image-guided percutaneous transthoracic needle biopsy (PTNB) is a widely accepted technique for characterization of pulmonary mass that is not reachable by broncoscopy. CT has been considered as the technique of choice for guiding PTNB procedures as it enables detailed visualization of the lesion and surrounding tissue structures. This technique offers good in-plane resolution. However, the view is limited to the plane that the needle is inserted, causing double-oblique approach with an angulated needle trajectory which is difficult to perform, time consuming (25–27 minutes), and heavily relies on the experience of the clinicians (3). The introduction of CT fluoroscopy (CTF) enables real-time visualization of the needle advancement. Thus, the challenges correlated with displacement and disappearance of small lesions from scan planes due to respiratory movement in conventional CT-guided PTNB can be overcome, leading to a reduced procedural time (12–24 minutes) (4). Nevertheless, CTF may result in higher radiation dose to clinicians (5–9). Besides, according to previous studies, lesion size is a determining factor in diagnostic accuracy of CT- or CTF-guided PTNB, which yields 75%–90% diagnostic accuracy, with correlated rates of 15%–20% for pneumothorax and 2%–3% for pneumothorax requiring drainage (10–14). In addition, due to the limited size of the gantry, CT- or CTF-guided PTNB procedures in obese patients can be technically challenging or impossible.Nowadays, flat detector-equipped angiographic C-arm cone-beam CT (CBCT) systems can be used to acquire CT-like cross-sectional images directly within the interventional radiology suite (15–17). The CBCT systems offer real-time visualization of PTNB procedure and more flexibility in the orientation of the detector system around the patient compared to traditional CT systems. Thus, CBCT could provide image guidance for PTNB procedures, combining the advantages of CT and fluoroscopic guidance, as it is proved to be valuable for evaluating pulmonary lesions even smaller than 2 cm. This technique has been shown to yield 90%– 98% diagnostic accuracy, 94%–97% sensitivity, and 75%–100% specificity. The incidence of complications was 20%–39%, the associated procedural time ranged 11.9–18.1 minutes and exposure dose ranged 170–275 mGy (3, 18–24). Along with the development of CBCT, a novel technique has recently emerged for PTNB guidance. It combines advanced virtual needle path planning based on user interactions using three-dimensional (3D) CBCT images with real-time fluoroscopic guidance (21, 25). This technique offers high spatial resolution of less than 1 mm, as well as contrast resolution of 10 HU, which is adequate for lung imaging, as lung inherently has a high contrast (soft tissue against air). In addition, CBCT allows good access to the patient without any patient transfer or movement, increasing the effectiveness and efficacy of clinical workflow.The purpose of this study is to explore the value of using a CBCT-based 3D needle guidance system in performing PTNB for pulmonary lesions in the interventional radiology suite.     

CT-guided percutaneous cryoablation of central lung tumors

PURPOSE

Cryoablation has been successfully used to treat lung tumors. However, the safety and effectiveness of treating tumors adjacent to critical structures has not been fully established. We describe our experience with computed tomography (CT)-guided percutaneous cryoablation of central lung tumors and the role of ice ball monitoring.

MATERIALS AND METHODS

Eight patients with 11 malignant central lung tumors (nine metastatic, two primary; mean, 2.6 cm; range, 1.0–4.5 cm) located adjacent to mediastinal or hilar structures were treated using CT-guided cryoablation in 10 procedures. Technical success and effectiveness rates were calculated, complications were tabulated and intraprocedural imaging features of ice balls were described.

RESULTS

All procedures were technically successful; imaging after 24 hours demonstrated no residual tumor. Five tumors recurred, three of which were re-ablated successfully. A hypodense ice ball with well-defined margin was visible during the first (n=6, 55%) or second (n=11, 100%) freeze, encompassing the entire tumor in all patients, and abutting (n=7) or minimally involving (n=4) adjacent mediastinal and hilar structures. Pneumothorax developed following six procedures (60%); percutaneous treatment was applied in three of them. All patients developed pleural effusions, with one patient requiring percutaneous drainage. Transient hemoptysis occurred after six procedures (60%), but all cases improved within a week. No injury occurred to mediastinal or hilar structures.

CONCLUSION

CT-guided percutaneous cryoablation can be used to treat central lung tumors successfully. Although complications were common, they were self-limited, treatable, and not related to tumor location. Ice ball monitoring helped maximize the amount of tumor treated, while avoiding critical mediastinal and hilar structures.Malignant lung tumors represent a major cause of morbidity and mortality in developed nations (1). While surgical resection remains the treatment of choice for the local control of both non-small cell lung cancer and metastases to the lung, percutaneous image-guided ablative therapies, particularly heat-based ablation techniques such as radiofrequency (RF) ablation, have emerged as safe and effective alternatives in patients who are not surgical candidates (2–7). However, treatment of lung tumors using RF ablation presents technical challenges, including high electrical resistance of alveolar air, poor thermal conductivity of aerated lung, and the heat-sink effect of blood and air flow in well-perfused and aerated lung tissue (8, 9). In addition, RF ablation has a limited role in the treatment of tumors that are close to mediastinal and hilar structures (2–9). Since intraprocedural visualization of ablation zone margins is not possible during heat-based ablation procedures, treatment of central tumors could harm mediastinal and hilar structures, including the tracheobronchial tree. As a result, tumors close to central structures are generally not amenable to treatment using percutaneous heat-based ablation techniques (2–10). Also, RF ablation may interfere with conduction system of the heart and function of the pacemakers (11).A growing body of literature describes the successful use of cryoablation in the treatment of malignancies in the liver, kidneys, and soft tissues (12–14). The ability to deploy multiple, individually-controlled cryoablation applicators facilitates the creation of ablation zones of desired shapes and sizes that can be tailored to the morphology of the tumor being ablated (15, 16). Cryoablation is also monitorable; ice balls can be visualized by computed tomography (CT) as a distinct ovoid area of low attenuation during the procedure. As a result, the treatment can be optimized while minimizing the risk of harming nearby critical structures (12–16). Also, cryoablation may be less painful than RF ablation (17). Finally, it has been suggested that cryoablation may be better suited for the treatment of thoracic tumors adjacent to the mediastinum because it spares the architecture of collagen-containing structures relative to RF ablation and enables preservation of the integrity of the tracheobroncheal tree (18). Heat-based ablation methods may not be safe in the treatment of central lung tumors because of a possibility of bronchial disruption or perforation, which may result in bronchopleural fistula formation (19). Although cryoablation has been used to treat lung malignancies (19–31), there are limited data on the safety and effectiveness of percutaneous cryoablation of central lung tumors. In this study, we describe our experience with CT-guided percutaneous cryoablation of central lung tumors and the role of ice ball monitoring.     

Paratracheal air cysts: prevalence and relevance to pulmonary emphysema and bronchiectasis using thoracic multidetector CT

PURPOSE

We aimed to determine the prevalence of paratracheal air cysts (PTACs) and the relationship of PTACs with emphysema and bronchiectasis through retrospective analysis of multidetector computed tomography (MDCT) findings.

METHODS

MDCT findings of 1027 consecutive patients who underwent routine thorax examination between January 2012 and January 2013 were evaluated retrospectively for the presence of PTACs. Localization of the PTACs, as well as their size, shape, and relationship with the trachea were examined. Presence of emphysema and bronchiectasis was recorded, and bronchiectasis severity index was calculated when present. We randomly selected 80 patients who had no visible PTACs as the control group. The findings of patients with and without PTACs were compared.

RESULTS

PTACs were determined in 82 of 1027 patients (8%), in 8.8% of females and 7.3% of males. The presence of PTACs was determined to be independent of gender (P = 0.361). Eighty-one PTACs (98.8%) were located in the right side of the trachea and 56.1% had a tracheal connection. The presence of PTACs significantly correlated with the presence and severity of bronchiectasis (P = 0.001 and P = 0.005 respectively). There was no significant relationship between the presence of PTACs and the presence of emphysema on CT images (P = 0.125).

CONCLUSION

The prevalence of PTACs was determined as 8% in this study. There was significant association between PTACs and bronchiectasis.Paratracheal air cysts (PTACs) are small collections of air adjacent to the trachea at the level of the thoracic inlet (1). Pathological diagnosis of PTACs in surgically confirmed cases includes tracheal diverticulum, lymphoepithelial cyst, and bronchogenic cyst (1–3). These cysts are covered with ciliary columnar epithelium and connected with the trachea (4). The majority of PTACs are reported as tracheal diverticula in the literature, due to their connection with the trachea (2). The thoracic inlet between the cartilage and muscle layers in right posterolateral wall of the trachea is the most common location for PTACs. A relationship may be seen between an isolated PTAC and the trachea l lumen (5). These lesions may cause recurrent infections by acting as a reservoir for secretions.Occasionally, PTACs can be confused with other causes of extraluminal air collections as laryngocele, pharyngocele, Zenker’s diverticulum, apical hernia of the lung, mediastinal air, apical paraseptal blebs, or bullae. To distinguish PTACs from other pathologies, its typical location in the right posterior paratracheal region at the thoracic inlet can be helpful: PTACs locate away from the lung pleura, communicate with the trachea and have rounded margins that can be differentiated from emphysematous changes (6).PTACs are usually discovered incidentally on thorax computed tomography (CT). They may be associated with a chronic cough or chronic obstructive pulmonary diseases (COPD). The reported prevalence of PTACs ranges from 0.75% to 8.1% (4, 6–8). There have been a limited number of studies reporting the incidence of PTACs related to COPD or emphysema as detected by CT, and the reported results are variable (4, 6, 8–11). The relationship between PTACs and pulmonary emphysema or bronchiectasis is still unclear. To our knowledge, no published study has evaluated the relationship between PTACs and bronchiectasis, using a bronchiectasis severity index and objective measures to determine the extent of bronchiectasis on CT images.The purpose of our study was to evaluate the prevalence and characteristics of PTACs, as well as their relationship with bronchiectasis and emphysema, on thorax CT scans.     

Clinical effect of double coaxial self-expandable metallic stent in management of malignant colon obstruction

PURPOSE

We aimed to evaluate the clinical effectiveness and safety of double coaxial self-expandable metallic stent (DCSEMS) in management of malignant colonic obstruction as a bridge to surgery or palliation for inoperable patients.

METHODS

Between April 2006 and December 2012, 49 patients (27 males and 22 females; median age, 68 years; age range, 38–91 years) were selected to receive decompressive therapy for malignant colonic obstruction by implanting a DCSEMS. Application of DCSEMS was attempted in 49 patients under fluoroscopic guidance. The obstruction was located in the transverse colon (n=2), descending colon (n=7), sigmoid colon (n=24), rectosigmoid junction (n=6), and the rectum (n=10). The intended use of DCSEMS was as a bridge to elective surgery in 23 patients and palliation in 26 patients.

RESULTS

Clinical success, defined as >50% dilatation of the stent with subsequent symptomatic improvement, was achieved in 48 of 49 patients (98%). The stent was properly inserted in all patients. No immediate major procedure-related complications occurred. One patient in the bridge-to-surgery group had colon perforation three days after DCSEMS application. Four patients had late migrations of the double stent.

CONCLUSION

Application of DCSEMS is safe and effective in management of malignant colonic obstruction; it prevents stent migration and tumor ingrowth and lowers perforation rate during the stent application.Fluoroscopic or endoscopic placement of either bare or covered expandable metallic stents was shown to be a safe, easy, and effective technique as a bridge to surgery and palliative treatment of colorectal cancer (1, 2). However, tumor ingrowth and stent migration have been reported as weaknesses in conventional single bare and covered stents, respectively (2–4). The use of bare stents has been hindered by progressive tumor ingrowth through the wire filaments of the bare stents and food residue or hard fecal impaction proximal to or at the level of the stent insertion site (5, 6). In contrast, the use of covered expandable metallic stents has been associated with stent migration (5, 7). To overcome the limitations associated with conventional bare and covered stents, a double coaxial self-expandable metallic stent (DCSEMS) has been developed to combine the strengths of bare and covered stents (7, 8).The purpose of the present study was to report our experiences with fluoroscopic-guided placement of double stents in management of malignant colorectal obstruction as a bridge to surgery or palliative treatment.     

Computed tomography arterial portography for assessment of portal vein injury after blunt hepatic trauma

PURPOSE

Intrahepatic portal vein injuries secondary to blunt abdominal trauma are difficult to diagnose and can result in insidious bleeding. We aimed to compare computed tomography arterial portography (CTAP), reperfusion CTAP (rCTAP), and conventional computed tomography (CT) for diagnosing portal vein injuries after blunt hepatic trauma.

METHODS

Patients with blunt hepatic trauma, who were eligible for nonoperative management, underwent CTAP, rCTAP, and CT. The number and size of perfusion defects observed using the three methods were compared.

RESULTS

A total of 13 patients (seven males/six females) with a mean age of 34.5±14.1 years were included in the study. A total of 36 hepatic segments had perfusion defects on rCTAP and CT, while there were 47 hepatic segments with perfusion defects on CTAP. The size of perfusion defects on CT (239 cm³; interquartile range [IQR]: 129.5, 309.5) and rCTAP (238 cm³; IQR: 129.5, 310.5) were significantly smaller compared with CTAP (291 cm³; IQR: 136, 371) (both, P = 0.002).

CONCLUSION

Perfusion defects measured by CTAP were significantly greater than those determined by either rCTAP or CT in cases of blunt hepatic trauma. This finding suggests that CTAP is superior to rCTAP and CT in evaluating portal vein injuries after blunt liver trauma.The liver is one of the most frequently injured solid abdominal organs in the setting of blunt abdominal trauma (1). Fortunately, most patients with blunt hepatic trauma have relatively stable vital signs and need only supportive treatment or transarterial embolization (TAE) (1–9). Only 15% of patients, who present with hemodynamic instability or fail with nonoperative management, require operative intervention to manage their liver injury.Embolic therapy has been shown to have a high success rate in hemodynamically stable patients with blunt hepatic injury. TAE is associated with decreased abdominal infections, decreased transfusions, and decreased length of hospital stay compared with operative management (2, 3, 7). However, angiography can only detect bleeding from the hepatic artery; it cannot locate bleeding from the hepatic or portal vein. In the literature, portal vein injuries are not commonly described and most are the result of penetrating injuries to the extrahepatic portal veins. Mortality after a portal vein injury due to trauma is primarily due to hypovolemic shock and can be as high as 50% or greater (10, 11).Since the intrahepatic portions of the hepatic and portal veins are low pressure systems, they can bleed insidiously. Nevertheless, this subtle bleeding may require multiple transfusions and result in a prolonged hospital stay. Relative to an extrahepatic portal vein injury, patients with an intrahepatic portal vein injury may have relatively stable vital signs and slowly decreasing hemoglobin levels (10, 11). In addition, traumatic occlusion and/or thrombosis of the portal vein may cause large hepatic parenchymal infarction.Computed tomography arterial portography (CTAP) is a useful method based on portal enhancement of the liver by infusion of contrast material through the superior mesenteric artery for evaluating the portal venous system (12–15) and is widely used in patients with hepatic tumors with portal venous invasion (13, 16, 17). CTAP has a high sensitivity and specificity in the evaluation of portal vein thrombosis due to tumor (90% sensitivity, 99% specificity, 95% positive predictive value, 97% negative predictive value) (14). However, few studies have focused specifically on the utility of CTAP in the evaluation of portal vein injury as a result of trauma.The liver has a dual blood supply and receives between 66% and 75% of its blood supply from the hepatic portal vein with the remainder supplied by the hepatic artery (18). CTAP reflects only portal venous perfusion while reperfusion CTAP (rCTAP) reflects hepatic arterial reperfusion. Both rCTAP and conventional computed tomography (CT) are useful for determining certain liver injuries. However, they do not specifically evaluate the portal vein.The purpose of this study was to compare CTAP, rCTAP, and CT for diagnosing portal vein injuries after blunt hepatic trauma. We hypothesized that CTAP would be superior to rCTAP and CT in assessing portal vein injury after blunt hepatic trauma.     

Added value of diffusion-weighted MRI in detection of cervical cancer recurrence: comparison with morphologic and dynamic contrast-enhanced MRI sequences

PURPOSE

We aimed to evaluate the added value of diffusion-weighted imaging (DWI) to standard magnetic resonance imaging (MRI) for detecting post-treatment cervical cancer recurrence. The detection accuracy of T2-weighted (T2W) images was compared with that of T2W MRI combined with either dynamic contrast-enhanced (DCE) MRI or DWI.

METHODS

Thirty-eight women with clinically suspected uterine cervical cancer recurrence more than six months after treatment completion were examined with 1.5 Tesla MRI including T2W, DCE, and DWI sequences. Disease was confirmed histologically and correlated with MRI findings. The diagnostic performance of T2W imaging and its combination with either DCE or DWI were analyzed. Sensitivity, positive predictive value, and accuracy were calculated.

RESULTS

Thirty-six women had histologically proven recurrence. The accuracy for recurrence detection was 80% with T2W/DCE MRI and 92.1% with T2W/DWI. The addition of DCE sequences did not significantly improve the diagnostic ability of T2W imaging, and this sequence combination misclassified two patients as falsely positive and seven as falsely negative. The T2W/DWI combination revealed a positive predictive value of 100% and only three false negatives.

CONCLUSION

The addition of DWI to T2W sequences considerably improved the diagnostic ability of MRI. Our results support the inclusion of DWI in the initial MRI protocol for the detection of cervical cancer recurrence, leaving DCE sequences as an option for uncertain cases.Cervical cancer is the fourth most frequent cancer in women worldwide (1). Early stage disease is treated with surgery or chemoradiotherapy and has a good prognosis. However, around 30% of all patients treated for cervical carcinoma develop progressive or recurrent tumors (2).Recurrent cervical cancer is defined as local tumor regrowth or the development of distant organ/lymph node metastases at least six months after regression of the initial lesion. Approximately two-thirds of recurrences appear within the first two years following initial treatment, with 90% recurring by five years post-treatment (3). Risk factors for recurrence include histopathologic features, depth of tumor invasion, and nodal status (4).Pelvic recurrence can be located centrally (cervix, uterus, vagina, parametria, ovaries, bladder, or rectum) or in the pelvic sidewalls. Extrapelvic recurrence most commonly involves the para-aortic lymph nodes, lungs, liver, or bone (4–6).Treatment of recurrent cancer depends on the primary treatment approach, location, and extension. Patients with locally recurrent disease can be offered salvage treatments with curative potential (chemoradiotherapy, if not given previously, or pelvic exenteration in patients who already received chemoradiotherapy). Distant metastases, however, are nearly always incurable (3).In patients who successfully completed primary treatment, surveillance has been advocated to detect the residual or recurrent disease at curable stages (7). The use of imaging studies such as magnetic resonance imaging (MRI) is indicated on the basis of clinical suspicion (8).T2-weighted (T2W) imaging is the reference sequence for cervical cancer staging (9). Recurrent tumors are known to show high signal intensity on T2W MRI, contrasting with the low signal intensity of the cervical stroma. However, some benign conditions such as necrosis, inflammation, and edema may also increase signal intensity on T2W images, representing a potential challenge to the radiologist, particularly after radiotherapy (10–13).Moreover, post-treatment changes can result in areas of fibrosis that are also difficult to differentiate from recurrence (14). MRI has proven to be superior to computed tomography (CT) in distinguishing fibrosis and scarring from active disease, but imaging findings are sometimes indeterminate, complicating the evaluation of recurrent disease (3).In recent years, the functional MRI techniques such as dynamic multiphase contrast-enhanced (DCE) MRI and diffusion-weighted imaging (DWI) have emerged as fundamental tools in female pelvic imaging evaluation (15). Although DCE was shown to be more accurate than T2W alone for tumor recurrence identification, the use of both sequences is recommended (10).Recently, DWI has been added to pelvic MRI protocols to increase diagnostic accuracy in tumor staging. This technique is a functional tool that relies on tissue water displacement to create a contrasted image. For correct evaluation and avoidance of pitfalls, the generated images must be interpreted alongside anatomical sequences. The apparent diffusion coefficient (ADC) map is also needed to reduce image misinterpretation, for example due to the T2 shine-through effect (15). In highly cellular tissues, water movement is restricted and such lesions appear bright at high b-values (1000 s/mm²) and have low ADC value, appearing dark gray on ADC maps in contrast to areas of freely moving water such as urine in the bladder (14). Some recent studies have suggested that DWI and ADC maps can be potentially useful in oncologic follow-up (14, 16).The purpose of this study was to compare the accuracy of T2W/DWI with that of conventional anatomical sequences alone and T2W/DCE imaging sequences in the evaluation of recurrent disease in patients treated for uterine cervical carcinoma.     

Can unenhanced breast MRI be used to decrease negative biopsy rates?

PURPOSE

We aimed to determine whether low-risk breast masses can be effectively managed with unenhanced magnetic resonance imaging (MRI) combining T2-weighted sequences with diffusion-weighted imaging (DWI) instead of immediate biopsy to decrease negative biopsy rates.

METHODS

After institutional review board and patient approvals, 141 consecutive women with 156 low-risk breast masses, who underwent unenhanced MRI and later on received a final diagnosis, were included in the study. There were 72 BI-RADS 3 masses in women with relative risk factors and 84 BI-RADS 4A masses, all referred for biopsy. Apparent diffusion coefficient (ADC) cutoff was 0.90×10-3 mm2/s. According to ADC values and T2-weighted imaging characteristics, masses were classified as either malignant or benign. Unenhanced MRI results were compared with final diagnoses obtained by histopathology or imaging surveillance, and diagnostic values were calculated.

RESULTS

Of 156 masses, 112 underwent biopsy. Four malignancies were diagnosed, three of which having ADC values lower than the cutoff. In women who rejected the biopsy, masses were stable during a follow-up of at least two years (n=44). MRI revealed 91% specificity and 99% negative predictive value (NPV) for detection of breast cancer.

CONCLUSION

Combination of T2-weighted imaging with DWI is a feasible method to further characterize breast masses with a low probability of malignancy. With the use of unenhanced MRI instead of immediate biopsy, it might be possible to decrease negative biopsy rates of low-risk breast masses.The Breast Imaging Reporting and Data Systems (BI-RADS) lexicon (1) of American College of Radiology (ACR) provides an efficient and standardized assessment and management of breast lesions. It also stratifies breast cancer risk for a given lesion by classifying them into categories 1 through 5 according to the degree of suspicion.According to this system, solid masses with a circumscribed margin, oval shape (including those with two or three gentle lobulations) and parallel orientation on ultrasonography (US) exam are classified as BI-RADS 3. These types of masses are commonly seen at diagnostic and screening examinations. In this category malignancy is highly unlikely (less than 2%) and a short interval follow-up is recommended (1). However, up to one-third of such masses undergo biopsy mainly because of radiologist, referring clinician, or patient concern about the substantial risk of malignancy (2–4). Many BI-RADS 3 masses are traditionally referred for biopsy if they are palpable, large in size, patient is of advanced age or has a positive family history for breast cancer.The BI-RADS 4 assessment is reserved for findings that do not have the classic appearance of malignancy but are sufficiently suspicious to justify a recommendation for biopsy. This category is largely indeterminate and highly variable in outcome. Breast lesions in this category carry 2% to 95% risk for malignancy (1). Thus, almost all recommendations for breast biopsies come from assessments made using this category. According to BI-RADS classification; category 4 is subgrouped as 4A, 4B, and 4C to better inform the clinicians, pathologists, and patients of the degree of concern. However, the criteria for distinguishing among these subcategories have not been well delineated. BI-RADS 4A designates lesions with a low suspicion for malignancy. In this group, a benign pathologic diagnosis is expected and considered concordant (1). Studies of several institutions by the use of their internal criteria revealed positive predictive value (PPV) of 7%–9% for 4A lesions, and more than 50% of the suspicious lesions fall into this category. On the other hand, BI-RADS 4B and 4C designate lesions with moderate and high suspicion for malignancy and PPV in these categories were reported to be 19%–38% and 57%–82%, respectively (5–7).Approximately 70%–80% of breast biopsies result in benign diagnosis (8, 9). Although the risk of malignancy is low, many BI-RADS 3 masses and all subcategory 4A masses are referred for biopsy. These two groups constitute the main source of negative biopsies which load unnecessary fear, anxiety, discomfort, pain, and financial cost to these patients.Breast magnetic resonance imaging (MRI) is a well-established advanced technique for evaluation of the breast masses. Dynamic contrast-enhanced (DCE) imaging has high sensitivity, and it is the most proposed breast MRI method. However, this method is time consuming, needs contrast injection, has moderate specificity, and is relatively difficult to evaluate (10–12). DCE MRI evaluation of all low-risk lesions recommended for biopsy would not be cost effective. On the other hand, diffusion weighted imaging (DWI) is a newly proposed and highly effective MRI technique used for characterization of breast lesions, especially of masses, by measuring the random motion of free water protons in tissues. DWI is easy to evaluate, does not require contrast injection, has short imaging time and shows higher specificity (reported to be 84% in a meta-analysis) than DCE imaging (13).The purpose of this study was to investigate the value of unenhanced MRI combining T2-weighted sequences with DWI for further characterization of breast masses having a low probability of being malignant (BI-RADS 3 and 4A). We hypothesized that unnecessary breast biopsies performed for benign masses might be decreased by evaluating these masses with unenhanced MRI.     

Percutaneous transluminal balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: technical success and analysis of factors affecting postprocedural fistula patency

PURPOSE

We aimed to determine the predictors of technical success and patency after percutaneous transluminal angioplasty (PTA) of de novo dysfunctional hemodialysis arteriovenous fistulas (AVF).

METHODS

We performed a retrospective analysis of first time PTA in 228 patients (129 men, 99 women; mean age, 56.8±14.6 years). Anatomical (location, length, grade, and number of stenoses) and clinical variables (sex, age, prior AVF, diabetes mellitus, AVF age, side, and location) were reviewed.

RESULTS

A total of 330 stenoses were found in 228 patients. PTA was technically successful in 96.3% of the stenoses (n=319). Clinical success was achieved in 97.2% (n=321). Early dysfunction (within six months) was positively correlated with patient age (P < 0.001) and diabetes (P < 0.005). Older age (P < 0.001) and diabetes (P = 0.002) were associated with a lower primary patency rate. Patient age (P < 0.001), presence of diabetes (P = 0.023), length of stenosis (P = 0.003), early recurrence (P = 0.003) and presence of residual stenosis (P = 0.014) were associated with a lower secondary patency rate.

CONCLUSION

Patency of dysfunctional hemodialysis fistulas can be maintained safely with continuous follow-up and repeated interventions without shortening the venous segment by surgical revision. Percutaneous approach to hemodialysis access stenosis is an alternative to the conventional surgical approach and PTA is an effective treatment method for dysfunctional AVF.Hemodialysis, and therefore patent hemodialysis access, is of great importance to patients with end-stage renal disease (ESRD). The preferred type of access in patients undergoing hemodialysis is an arteriovenous fistula (AVF) (1). The Kidney Disease Outcomes Quality Initiative provides evidence-based clinical practice guidelines for all stages of ESRD and reports autogenous AVF as the reference standard for primary vascular access, due to their longevity and low infection rates (2, 3). Sands et al. (4) and Schwab et al. (5) demonstrated a 10-fold increase in thrombosis rate of synthetic polytetrafluoroethylene (PTFE) accesses when compared to AVFs. Despite proven advantages of AVF over PTFE, both types of access eventually fail and contribute to multiple hospital admissions, radiological and surgical interventions, and overall morbidity associated with chronic hemodialysis. Significant stenosis causing access dysfunction is a frequent complication in hemodialysis and requires repeated percutaneous transluminal balloon angioplasty (PTA) to maintain patency (6–9). The patency of PTA is limited, however, with first year primary patency rates ranging between 26% and 62% (6–8). Many factors influencing the patency rate have been studied in previously reported series (7, 8). Our study is the first to investigate the effect of early recurrence on secondary patency.